$VTYX
Ventyx Biosciences, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023041347 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.200M $8.585M
YoY Change 37.77% 50.03%
% of Gross Profit
Research & Development $49.75M $48.56M
YoY Change 95.34% 230.88%
% of Gross Profit
Depreciation & Amortization $30.00K $34.00K
YoY Change -6.25% 41.67%
% of Gross Profit
Operating Expenses $57.95M $57.15M
YoY Change 84.44% 180.15%
Operating Profit -$57.95M -$57.15M
YoY Change 84.44% 180.15%
Interest Expense $3.930M $3.899M
YoY Change
% of Operating Profit
Other Income/Expense, Net $3.924M $3.894M
YoY Change 309.6% 924.74%
Pretax Income -$54.03M -$53.25M
YoY Change 77.37% 166.02%
Income Tax
% Of Pretax Income
Net Earnings -$54.03M -$53.25M
YoY Change 77.36% 166.02%
Net Earnings / Revenue
Basic Earnings Per Share -$0.92 -$0.91
Diluted Earnings Per Share -$0.92 -$0.91
COMMON SHARES
Basic Shares Outstanding 58.89M 58.56M
Diluted Shares Outstanding 58.88M 58.56M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $300.8M $332.3M
YoY Change -27.07% 32.66%
Cash & Equivalents $56.61M $51.72M
Short-Term Investments $244.2M $280.5M
Other Short-Term Assets $7.300M $14.45M
YoY Change 22.34% 729.93%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $308.1M $346.7M
YoY Change -26.36% 37.47%
LONG-TERM ASSETS
Property, Plant & Equipment $686.0K $629.0K
YoY Change 93.79% 119.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0%
Other Assets $102.0K $102.0K
YoY Change 41.67% 41.67%
Total Long-Term Assets $13.61M $2.062M
YoY Change 562.24% -79.36%
TOTAL ASSETS
Total Short-Term Assets $308.1M $346.7M
Total Long-Term Assets $13.61M $2.062M
Total Assets $321.7M $348.8M
YoY Change -23.49% 33.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.338M $4.085M
YoY Change -49.75% -29.63%
Accrued Expenses $16.39M $15.51M
YoY Change -1.76% 35.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.21M $20.03M
YoY Change -26.51% 13.35%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $11.90M $922.0K
YoY Change 851.24% -32.16%
Total Long-Term Liabilities $11.90M $922.0K
YoY Change 851.24% -32.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.21M $20.03M
Total Long-Term Liabilities $11.90M $922.0K
Total Liabilities $38.06M $20.96M
YoY Change 3.11% 10.1%
SHAREHOLDERS EQUITY
Retained Earnings -$372.4M -$318.4M
YoY Change 94.98% 98.32%
Common Stock $6.000K $6.000K
YoY Change 0.0% 20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $283.6M $327.8M
YoY Change
Total Liabilities & Shareholders Equity $321.7M $348.8M
YoY Change -23.49% 33.02%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$54.03M -$53.25M
YoY Change 77.36% 166.02%
Depreciation, Depletion And Amortization $30.00K $34.00K
YoY Change -6.25% 41.67%
Cash From Operating Activities -$34.67M -$49.28M
YoY Change 44.52% 233.17%
INVESTING ACTIVITIES
Capital Expenditures $40.00K $195.0K
YoY Change -141.24% -796.43%
Acquisitions
YoY Change
Other Investing Activities $38.94M $35.01M
YoY Change -39.4% 91.56%
Cash From Investing Activities $38.90M $34.82M
YoY Change -39.37% 90.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.620M 2.473M
YoY Change -99.09% 893.17%
NET CHANGE
Cash From Operating Activities -34.67M -49.28M
Cash From Investing Activities 38.90M 34.82M
Cash From Financing Activities 1.620M 2.473M
Net Change In Cash 5.850M -11.99M
YoY Change -97.32% -423.44%
FREE CASH FLOW
Cash From Operating Activities -$34.67M -$49.28M
Capital Expenditures $40.00K $195.0K
Free Cash Flow -$34.71M -$49.48M
YoY Change 45.28% 235.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001851194
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssets
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssets
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40928
dei Entity Registrant Name
EntityRegistrantName
Ventyx Biosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2996852
dei Entity Address Address Line1
EntityAddressAddressLine1
12790 El Camino Real
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
760
dei Local Phone Number
LocalPhoneNumber
593-4832
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58743101
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57025847
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58713982
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
VTYX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58888436
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51717000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64819000
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
280535000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
253122000
CY2023Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
14449000
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
12747000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
346701000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
330688000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
629000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
407000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1331000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1537000
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
38672000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
102000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
96000
CY2023Q2 us-gaap Assets
Assets
348763000
CY2022Q4 us-gaap Assets
Assets
371400000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4085000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6433000
CY2023Q2 vtyx Accrued Expenses Related Party
AccruedExpensesRelatedParty
0
CY2022Q4 vtyx Accrued Expenses Related Party
AccruedExpensesRelatedParty
64000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15510000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9514000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
439000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
412000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
20034000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16359000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
922000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1146000
CY2023Q2 us-gaap Liabilities
Liabilities
20956000
CY2022Q4 us-gaap Liabilities
Liabilities
17505000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56980845
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
646918000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
581237000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-710000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1123000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-318407000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-226225000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
327807000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
353895000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
348763000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
371400000
CY2023Q2 vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
109000
CY2022Q2 vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
230000
vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
359000
vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
433000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48560000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14676000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
83997000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32085000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8585000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5722000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15700000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11060000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
57145000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
20398000
us-gaap Operating Expenses
OperatingExpenses
99697000
us-gaap Operating Expenses
OperatingExpenses
43145000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-57145000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20398000
us-gaap Operating Income Loss
OperatingIncomeLoss
-99697000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43145000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3899000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
342000
us-gaap Investment Income Interest
InvestmentIncomeInterest
7521000
us-gaap Investment Income Interest
InvestmentIncomeInterest
474000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
38000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-79000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3894000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
380000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7515000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
395000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-53251000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-20018000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2624000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
214000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14435000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
352000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
61000
us-gaap Net Income Loss
NetIncomeLoss
-92182000
us-gaap Net Income Loss
NetIncomeLoss
-42750000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-187000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-279000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
352000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1221000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
38000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-54000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
61000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53400000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20351000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-91769000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43983000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58556529
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58556529
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50848391
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50848391
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58100261
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58100261
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50717548
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50717548
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
371618000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1507000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
214000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7868000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-187000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
38000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-53251000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
327807000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
259123000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
134000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
115000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4131000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-279000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-54000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-20018000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
243152000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
353895000
us-gaap Net Income Loss
NetIncomeLoss
-92182000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
327807000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
279199000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
220000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
115000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
26000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7575000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1221000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12000
us-gaap Net Income Loss
NetIncomeLoss
-42750000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
243152000
us-gaap Profit Loss
ProfitLoss
-92182000
us-gaap Profit Loss
ProfitLoss
-42750000
us-gaap Depreciation
Depreciation
65000
us-gaap Depreciation
Depreciation
45000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
208000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
148000
us-gaap Share Based Compensation
ShareBasedCompensation
14435000
us-gaap Share Based Compensation
ShareBasedCompensation
7575000
vtyx Accretion Of Marketable Securities
AccretionOfMarketableSecurities
-4569000
vtyx Accretion Of Marketable Securities
AccretionOfMarketableSecurities
-109000
vtyx Increase Decrease In Prepaid Expense And Other Assets Related Party Amounts
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsRelatedPartyAmounts
47000
vtyx Increase Decrease In Prepaid Expense And Other Assets Related Party Amounts
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsRelatedPartyAmounts
-0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1515000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2677000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-197000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-136000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-1000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
77000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2371000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1171000
vtyx Increase Decrease In Accrued Liabilities Related Party Amounts
IncreaseDecreaseInAccruedLiabilitiesRelatedPartyAmounts
-64000
vtyx Increase Decrease In Accrued Liabilities Related Party Amounts
IncreaseDecreaseInAccruedLiabilitiesRelatedPartyAmounts
-101000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5923000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3861000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-80203000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27518000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
172821000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
125397000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
189000000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
127210000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
255000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15924000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1747000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
48408000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2570000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
220000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
30
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
30
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
214000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
115000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
73000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
51119000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
335000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-12000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13102000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25448000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
64819000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70791000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51717000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
45343000
vtyx Deferred Offering Costs Unpaid
DeferredOfferingCostsUnpaid
66000
vtyx Exercise Of Stock Options
ExerciseOfStockOptions
54000
us-gaap Noncash Or Part Noncash Acquisition Inventory Acquired1
NoncashOrPartNoncashAcquisitionInventoryAcquired1
30000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
28
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
2
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
281275000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
745000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
280535000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
292886000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
20000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1112000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
291794000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
37
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
37
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
32
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
5
CY2023Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0
CY2023Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
1100000
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
900000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
790000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
502000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
161000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
95000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
629000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
407000
CY2023Q2 vtyx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6807000
CY2022Q4 vtyx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
2450000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3701000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4208000
CY2023Q2 vtyx Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
3625000
CY2022Q4 vtyx Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1235000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1377000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1557000
CY2023Q2 vtyx Accrued Related Party Liabilities Current
AccruedRelatedPartyLiabilitiesCurrent
0
CY2022Q4 vtyx Accrued Related Party Liabilities Current
AccruedRelatedPartyLiabilitiesCurrent
64000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15510000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9514000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of outstanding shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12756479
CY2021Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-06-30
CY2021Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-06-30
CY2021Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2024-06-30
us-gaap Lessee Operating Lease Option To Terminate
LesseeOperatingLeaseOptionToTerminate
The leases contain various termination options.
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
200000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1331000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1537000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
439000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
412000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
922000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1146000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1361000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1558000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
269000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
517000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
502000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
256000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1544000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
183000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1361000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
439000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
922000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7868000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4131000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14435000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7575000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7868000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4131000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14435000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7575000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7592856
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.82
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M26D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
159929000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2377839
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
35.04
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
521677
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.03
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
418306
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
24.21
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9030712
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M1D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
142093000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
9030712
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
17.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M1D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
142093000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3297128
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.40
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y18D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
77274000
vtyx Number Of Employees Terminated
NumberOfEmployeesTerminated
1
vtyx Number Of Employees Terminated
NumberOfEmployeesTerminated
2
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-53251000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-20018000
us-gaap Net Income Loss
NetIncomeLoss
-92182000
us-gaap Net Income Loss
NetIncomeLoss
-42750000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58556529
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58556529
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50848391
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50848391
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58100261
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58100261
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50717548
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50717548
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9829037
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8157816
CY2023Q2 vtyx Lessee Operating Lease Payments Under Sublease Remainder Of Fiscal Year
LesseeOperatingLeasePaymentsUnderSubleaseRemainderOfFiscalYear
204000
CY2023Q2 vtyx Lessee Operating Lease Payments Under Sublease Due Next Twelve Months
LesseeOperatingLeasePaymentsUnderSubleaseDueNextTwelveMonths
1681000
CY2023Q2 vtyx Lessee Operating Lease Payments Under Sublease Due Year Two
LesseeOperatingLeasePaymentsUnderSubleaseDueYearTwo
2073000
CY2023Q2 vtyx Lessee Operating Lease Payments Under Sublease Due Year Three
LesseeOperatingLeasePaymentsUnderSubleaseDueYearThree
2135000
CY2023Q2 vtyx Lessee Operating Lease Payments Under Sublease Due Year Four
LesseeOperatingLeasePaymentsUnderSubleaseDueYearFour
2199000
CY2023Q2 vtyx Lessee Operating Lease Payments Under Sublease Due After Year Four
LesseeOperatingLeasePaymentsUnderSubleaseDueAfterYearFour
8426000
CY2023Q2 vtyx Lessee Operating Lease Payments Under Sublease Due
LesseeOperatingLeasePaymentsUnderSubleaseDue
16718000

Files In Submission

Name View Source Status
0000950170-23-041347-index-headers.html Edgar Link pending
0000950170-23-041347-index.html Edgar Link pending
0000950170-23-041347.txt Edgar Link pending
0000950170-23-041347-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtyx-20230630.htm Edgar Link pending
vtyx-20230630.xsd Edgar Link pending
vtyx-ex31_1.htm Edgar Link pending
vtyx-ex31_2.htm Edgar Link pending
vtyx-ex32_1.htm Edgar Link pending
vtyx-ex32_2.htm Edgar Link pending
vtyx-ex3_1.htm Edgar Link pending
vtyx-20230630_def.xml Edgar Link unprocessable
vtyx-20230630_lab.xml Edgar Link unprocessable
vtyx-20230630_pre.xml Edgar Link unprocessable
vtyx-20230630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
vtyx-20230630_cal.xml Edgar Link unprocessable